Patent classifications
A61L24/08
HYDROGELS HAVING TUNABLE CROSS-LINKING DENSITIES AND REVERSIBLE PHASE TRANSITIONS AND METHODS FOR THEIR USE
Provided is a method that achieves tunable crosslinking and reversible phase transition of hydrogels. The method is useful for preparing 3D-printable hydrogel, for example, for wound healing, aneurysm treatment or tissue regeneration.
COATING-SECURING AGENT
Provided is a coating-fixing agent for transplanting a cell or a tissue onto the surface of an organ, intestinal membrane, peritoneal membrane, etc. Provided are: a formulation for coating and fixing a graft, the formulation comprising alginate; a formulation kit for coating and fixing a graft, comprising a formulation containing alginate and a divalent or higher valent metal salt in combination; and a method for transplanting a graft, comprising: transplanting the graft to a transplant site of a human or a non-human animal, and coating the graft with alginate.
COATING-SECURING AGENT
Provided is a coating-fixing agent for transplanting a cell or a tissue onto the surface of an organ, intestinal membrane, peritoneal membrane, etc. Provided are: a formulation for coating and fixing a graft, the formulation comprising alginate; a formulation kit for coating and fixing a graft, comprising a formulation containing alginate and a divalent or higher valent metal salt in combination; and a method for transplanting a graft, comprising: transplanting the graft to a transplant site of a human or a non-human animal, and coating the graft with alginate.
COATING-SECURING AGENT
Provided is a coating-fixing agent for transplanting a cell or a tissue onto the surface of an organ, intestinal membrane, peritoneal membrane, etc. Provided are: a formulation for coating and fixing a graft, the formulation comprising alginate; a formulation kit for coating and fixing a graft, comprising a formulation containing alginate and a divalent or higher valent metal salt in combination; and a method for transplanting a graft, comprising: transplanting the graft to a transplant site of a human or a non-human animal, and coating the graft with alginate.
INJECTION FORMULATION COMPOSITION CONTAINING MESENCHYMAL STEM CELL-HYDROGEL AND METHOD FOR PREPARING, FREEZING AND DEFROSTING SAME
The present invention relates to a composition containing injectable mesenchymal stem cell-hydrogel and a method of preparing the same. Specifically, in a mesenchymal stem cell-hydrogel composition for injection prepared by a method of the present invention, since stem cells are attached to scaffolds in hydrogel beads, the stem cells are not easily lost or killed after the injection, and thus there is an advantage that an engraftment rate increases since the paracrine effect of the stem cells is continuously exhibited, and the stem cells are gradually released as hydrogel is degraded. In addition, the present invention has an advantage that healthy cells can be used without damages in cell membranes since injection formulation can be prepared without a treatment with proteolytic enzymes, and also a cryopreservation solution is easily removed from the mesenchymal stem cell-hydrogel beads even after freezing and thawing.
INJECTION FORMULATION COMPOSITION CONTAINING MESENCHYMAL STEM CELL-HYDROGEL AND METHOD FOR PREPARING, FREEZING AND DEFROSTING SAME
The present invention relates to a composition containing injectable mesenchymal stem cell-hydrogel and a method of preparing the same. Specifically, in a mesenchymal stem cell-hydrogel composition for injection prepared by a method of the present invention, since stem cells are attached to scaffolds in hydrogel beads, the stem cells are not easily lost or killed after the injection, and thus there is an advantage that an engraftment rate increases since the paracrine effect of the stem cells is continuously exhibited, and the stem cells are gradually released as hydrogel is degraded. In addition, the present invention has an advantage that healthy cells can be used without damages in cell membranes since injection formulation can be prepared without a treatment with proteolytic enzymes, and also a cryopreservation solution is easily removed from the mesenchymal stem cell-hydrogel beads even after freezing and thawing.
Electroactive bioadhesive compositions
The present invention relates to electrochemically initiated bioadhesive compositions comprising biocompatible polymers containing derivatives of diazonium, arylsulfonium, or diaryliodonium in general, and to their use in tissue fixation, in particular.
Electroactive bioadhesive compositions
The present invention relates to electrochemically initiated bioadhesive compositions comprising biocompatible polymers containing derivatives of diazonium, arylsulfonium, or diaryliodonium in general, and to their use in tissue fixation, in particular.
SELF-GELLING WOUND CONTACT MATERIALS WITH IODINE DELIVERY
Disclosed embodiments relate to wound care materials and methods that comprise a self-gelling composition, configured to form a gel upon contacting fluid. The self-gelling composition is a substantially homogeneous mixture, and comprises fluid-absorbent particles loaded with iodine-based antimicrobial agent, a dehydrated hydrogel powder, and a polymer base, configured to allow dispensing the self-gelling composition from a syringe or tube and to prevent the self-gelling composition from gelling prior to contacting fluid. The gel performs one or more of the following tasks during a wear time, when applied at the wound: absorbing fluid or exudate, releasing iodine-based antimicrobial agent, achieving antimicrobial activities at the wound, remaining structurally integral and cohesive, protecting the wound from exposure to microorganisms, and facilitating healing. After a wear time of at least three days, the gel can be removed in two pieces or less and leave less than 5% residue by weight.
Phosphocalcic cement composition comprising blood
A method for promoting spine fusion inside intersomatic cages, comprising placing a fusion cage between two vertebral bodies, and injecting a bone cement paste inside said fusion cage, said bone cement paste containing a powder component comprising α-tricalcium phosphate (α-TCP) particles having an average size greater than or equal to 9 μm, and a liquid component comprising blood.